Latest operating income for AKER: $-14M.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2020
Trailing 12 months ending Dec 31, 2020
As of the most recent data (December 2020), AKER shows a operating income of $-14M. That compares with $-7.6M in the prior-year period — down 90.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, AKER's operating income is now $-14M (was $-7.6M) — a 90.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akers Biosciences is outperforming or lagging.
Tracking AKER's operating income over time shows whether Akers Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-14M That compares with $-7.6M in the prior-year period — down 90.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Akers Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-14M) with ownership activity and broader fundamentals.
Akers Biosciences's operating income is $-14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.